Janus kinase inhibitors have delivered on some, but not all, of the promises that were expected of them upon approval in 2012, a speaker said at EULAR 2022 Congress.“I am trying to bring to you arguments for why particular promises associated with JAK inhibition have been fulfilled and why others have not,” Hendrik Schulze-Koops, MD, of the Ludwig Maximilian University of Munich, said